Table 2

Associations between bone RANKL mRNA levels and serum RANKL levels and other listed parameters

Parameter

Males

Females

Versus RANKL mRNA (versus RANKL/OPG mRNA; r [P value])

Versus serum RANKL (r [P value])

Versus RANKL mRNA (r)

Versus serum RANKL (r)

BV/TV

-0.53 (0.052)

0.10 (0.745)

-0.04

-0.20

BS/BV

0.57 (0.034)

-0.30 (0.296)

-0.12

-0.03

Tb.Th

-0.67 (0.011)

0.34 (0.230)

0.09

-0.05

ES/BS

(0.705 [0.003])

-0.35 (0.216)

0.33

-0.07

OS/BS

(0.80 [0.0003])

-0.02 (0.935)

0.28

0.03

ALP

(0.64 [0.011])

-0.49 (0.075)

0.07

0.08

OCN

0.71 (0.006)

-0.31 (0.283)

-0.02

-0.25

DPD

(0.85 [<0.0001])

-0.08 (0.785)

0.23

-0.25

Shown are correlations between receptor activator of nuclear factor-κB ligand (RANKL) mRNA levels (or RANKL mRNA/osteoprotegerin [OPG] mRNA) in bone and serum RANKL levels, and various structural parameters, static indices of bone turnover and biochemical bone turnover markers. ALP, alkaline phosphatase; BS/BV, specific surface of bone relative to bone tissue volume; BV/TV, bone volume fraction relative to bone tissue volume; DPD, deoxypyridinoline; ES/BS, eroded surface; OCN, osteocalcin; OS/BS, osteoid surface; Tb.Th, trabecular thickness.

Findlay et al. Arthritis Research & Therapy 2008 10:R2   doi:10.1186/ar2348